Article Information
History
- August 28, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Jean-Paul Pirnay1,66,#,
- Sarah Djebara2,66,
- Griet Steurs1,
- Johann Griselain1,
- Christel Cochez1,
- Steven De Soir1,
- Tea Glonti1,
- An Spiessens2,
- Emily Vanden Berghe2,
- Sabrina Green3,
- Jeroen Wagemans3,
- Cédric Lood3,
- Eddie Schrevens4,
- Nina Chanishvili5,
- Mzia Kutateladze5,
- Mathieu de Jode6,
- Pieter-Jan Ceyssens6,
- Jean-Pierre Draye1,
- Gilbert Verbeken1,
- Daniel De Vos1,
- Thomas Rose1,
- Jolien Onsea7,
- Brieuc Van Nieuwenhuyse8,
- Bacteriophage Therapy Providers*,
- Bacteriophage Donors**,
- Patrick Soentjens2,67,
- Rob Lavigne3,67 and
- Maya Merabishvili1,67
- 1Laboratory for Molecular and Cellular Technology, Queen Astrid military hospital, Brussels, Belgium
- 2Center for infectious diseases, Queen Astrid military hospital, Brussels, Belgium
- 3Laboratory of Gene Technology, Department of Biosystems, KU Leuven, Leuven, Belgium
- 4Department of Biosystems, KU Leuven, Leuven, Belgium
- 5Eliava Institute of Bacteriophages, Microbiology and Virology, Tbilisi, Georgia
- 6Bacterial Diseases, Sciensano, Brussels, Belgium
- 7Department of Trauma Surgery, University Hospitals Leuven; Department of Development and Regeneration, KU Leuven, Leuven, Belgium
- 8Institute of Experimental and Clinical Research, Pediatric Department, UCLouvain, Brussels, Belgium
- ↵#E-mail: jean-paul.pirnay{at}mil.be
↵66 These authors contributed equally: Jean-Paul Pirnay, Sarah Djebara
Posted August 28, 2023.
Retrospective, observational analysis of the first one hundred consecutive cases of personalized bacteriophage therapy of difficult-to-treat infections facilitated by a Belgian consortium
